Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Rigato M, Fadini GP, Avogaro A
Diabetes Obes Metab. Pub. online 4 Jul 2023.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
An update on the incidence of type 1 diabetes during the COVID-19 pandemic years
Giorda CB, Gnavi R, Tartaglino B, et al.
Diabetes Obes Metab. Pub. online 3 Jul 2023.
Leggi
Development and validation of a real‐world model to predict 1‐year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States)
Ratzki-Leewing AA, Black JE, Ryan BL, et al.
Diabetes Obes Metab. Pub. online 6 Jul 2023.
Leggi
Diabetic foot ulcers: a review
Armstrong DG, Tan TW, Boulton AJM, et al.
JAMA. 2023;330(1):62-75.
Leggi
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
Riley DR, Essa H, Austin P, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Doi Y, Hamano T, Yamaguchi S, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Zeng J, Gan S, Mi N, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
A comparison of faster insulin aspart to standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized, double-blind crossover trial
Dovc K, Bergford S, Fröhlich-Reiterer E, et al.
Diabetes Technol Ther. Pub. online 5 Jul 2023.
Leggi
Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study
Fan M, Stephan AJ, Emmert-Fees K, et al.
Diabetologia. Pub. online 30 Jun 2023.
Leggi
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials
Bjorner JB, Larsen S, Lübker C, Holst-Hansen T
Diabetes Obes Metab. 2023;25(8):2142-2150.
Leggi